However, cladribine has shown sensitivity against monocytic LSCs by targeting purine metabolism,28 and homoharringtonine‐based regimens have proven effective in RUNX1–RUNX1T1 AML, both in previous studies and in our findings.29, 30, 31. This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.